# Administration of Chlorpromazine as a Treatment for COVID-19

> **NCT04354805** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Cairo University** · enrollment: 100 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Chlorpromazine

## Key facts

- **NCT ID:** NCT04354805
- **Lead sponsor:** Cairo University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-08-01
- **Primary completion:** 2020-10
- **Final completion:** 2020-11
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2020-07-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04354805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04354805, "Administration of Chlorpromazine as a Treatment for COVID-19". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04354805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*